robinhood

Two Healthcare Stocks Poised for Recovery: Quest Diagnostics and IMS Health

Drinking the IMS coolaide, eh. Here is a stock that has been locked into $20-24 for the last eight years of ex-IBM management. None of the analysts covering IMS have made the legislative privacy challenges an issue and IMS (and NDC, Verispan) have won every battle to date. The ball and chain around this stock is pharma's slowdown from 15% growth to 5%. The story that IMS is needed more in tough times has lost its legs. Ruff, ruff - this stock is a dog.